Chemotherapy for Myelodysplastic Syndromes
Chemotherapy (chemo) is the use of drugs for treating a disease such as cancer. The drugs can be swallowed as pills, or they can be injected by needle into a vein or muscle. These drugs enter the bloodstream and reach most areas of the body and are considered systemic treatment. This type of treatment is useful for diseases such as myelodysplastic syndrome (MDS) that are not localized to one part of the body. The purpose of the chemo is to eliminate the abnormal stem cells and allow normal ones to grow back.
Because MDS can progress to acute myeloid leukemia (AML), patients with MDS may receive the same treatment as AML patients. The chemo drug most often used for MDS is called cytarabine (ara-C). It can be given by itself in a low-dose, which can help control the disease, but doesn’t often put it into remission. This treatment is also used for older patients with AML.
Another option is to give the same chemo that is used in younger patients with AML. This means giving cytarabine at a higher dose along with other chemo drugs. This is more often used for advanced MDS (like refractory anemia with excess blasts). For the treatment of MDS, the chemo drugs most often combined with cytarabine are:
Patients treated with the higher dose treatment are more likely to go into remission, but they have more severe side effects. These can lead to death. Still, this treatment may be an option for some patients with advanced MDS.
Using cytarabine by itself at a low dose has a lower chance of serious side effects (including death).
Chemo drugs can cause many side effects. The side effects depend on the type and dose of the drugs that are given and how long they are taken. Common side effects include:
- Hair loss
- Mouth sores
- Loss of appetite
- Nausea and vomiting
- Low blood counts
Chemo often slows blood production, leading to low blood counts. MDS patients already have low blood counts, which often become even worse for a time before they get better. Low white blood cell counts lead to an increased risk of serious infections. When platelet counts get low, patients have problems with easy bruising and can have serious bleeding, including bleeding into the brain or the intestine. Low red blood cell counts (or anemia) can lead to fatigue and shortness of breath. In people with heart problems, severe anemia can lead to a heart attack.
At times when their white blood cell counts are very low, patients may need to take steps to reduce their risk of infection, such as avoiding exposure crowds and being very careful about washing their hands. Some patients need to take antibiotics, which may be given before signs of infection or at the earliest sign that an infection may be developing. For more information about infections and ways to protect against them, see Infections in People With Cancer.
While their platelet counts are low, patients may receive platelet transfusions as to prevent or treat bleeding. Likewise, low red blood cell counts can be treated with red blood cell transfusions or with growth factors, such as erythropoietin (discussed below), to raise red blood cell counts. More information about transfusions can be found in Blood Transfusion and Donation.
Most side effects are temporary and will go away after treatment is finished. Your health care team often can suggest ways to lessen side effects. For example, other drugs can be given along with the chemo to prevent or reduce nausea and vomiting.
Chemo drugs can also affect other organs such as the kidneys, liver, testicles, ovaries, brain, heart, and lungs. For example, drugs like idarubicin can damage the heart, and so are often not given to patients who already have heart problems. Cytarabine can affect the brain and cause balance problems, sleepiness, and confusion. This is more common with higher doses of this drug. If serious side effects occur, the chemo treatments may have to be reduced or stopped, at least temporarily.
Carefully monitoring and adjusting drug doses are important because some of these side effects can be permanent.
These drugs are actually a form of chemo that affect the way genes are controlled. They help in MDS by slowing down genes that promote cell growth. They also kill cells that are dividing rapidly. Examples of this type of drug include azacitidine (Vidaza®) and decitabine (Dacogen®). In some MDS patients, these drugs improve blood counts, lower the chance of getting leukemia, and even prolong life. Red blood cell counts may improve enough to stop transfusions.
These drugs have some of the same side effects as regular chemo, but these side effects are usually mild. They include:
- Diarrhea or constipation
- Fatigue and weakness
- Low blood counts (most often the white blood cells or platelets)
Immune modulating drugs: The drugs thalidomide and lenalidomide (Revlimid®) belong to the class of drugs known as immunomodulating drugs (or IMiDs). Thalidomide was used first in treating MDS. It helped some patients, but many people stopped taking the drug because of side effects. Lenalidomide is a newer drug related to thalidomide that has fewer side effects. It seems to work well in low-grade MDS, eliminating the need for transfusions in about half the patients treated. The drug seems to work best in people whose MDS cells are missing a part of chromosome number 5 (this is called del(5q) or 5q-) and is approved by the FDA to treat these patients. It can also help MDS patients that do not have this abnormal chromosome.
Side effects include:
- Decreased blood counts (most often the white cell count and platelet count)
- Diarrhea or constipation
- Fatigue and weakness
Both of these drugs can also increase the risk of serious blood clots that start in the veins in the legs (called deep venous thrombosis or DVT). Part of a DVT can break off and travel to the lungs (called a pulmonary embolus or PE), where it can cause problems with breathing or even death. Many experts feel that patients getting this drug should also get some kind of treatment to prevent blood clots.
When thalidomide was first released in the 1960s, it caused serious birth defects when given to pregnant women. This led to the drug being taken off the market for many years. Now, it is only available through a special program of the drug company. Lenalidomide hasn’t been shown to cause birth defects, but concern about this risk has limited the availability of this drug as well. It is also only available through a program from the company that makes it.
Immunosuppression: Drugs that suppress the immune system can help some patients with MDS. These drugs are used more often in patients with aplastic anemia, a condition where the immune system attacks the bone marrow, leading to low blood counts. In MDS, these drugs are most helpful in patients with low numbers of cells in the bone marrow (called hypocellular bone marrow).
A drug called anti-thymocyte globulin (ATG) has helped some people, usually younger ones, with MDS. The drug is an antibody against a type of white blood cell called the T-lymphocyte. T-lymphocytes help control immune reactions. In some patients with MDS, T-lymphocytes interfere with normal blood cell production. ATG is given as an infusion through a vein. It must be given in the hospital because it can sometimes cause severe allergic reactions leading to low blood pressure and problems breathing.
Another drug that works by suppressing the immune system is called cyclosporine. It was first used to block immune responses in people who have had organ or bone marrow transplants, but it has helped some patients with MDS. Side effects of cyclosporine include loss of appetite and kidney damage.
Last Medical Review: February 10, 2014 Last Revised: July 2, 2015